Abstract:Cancer immunotherapy with ICB is considered a promising strategy for cancer treatment. In silico prediction of the ICB response is an important step toward achieving effective and personalized cancer immunotherapy. Three challenging issues remain: (i) Identifying highly predictive biomarkers by deciphering and understanding the interaction between tumor and immune cells; (ii) efficiently obtaining and predicting these biomarkers using HTS data; and (iii) building effective computational models that integrate these biomarkers for improved ICB response prediction. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. immune checkpoints are molecules in the immune system that either enhance or attenuate a signal. Tumors protect themselves from the immune system by inhibiting the T cell signal. The use of inhibitors to block inhibitory checkpoint molecules by recovering the anticancer immune response is referred to as ‘immune checkpoint blockade’. peptides presented by MHC class I or MHC class II molecules on the tumor cell surface. These peptides derive from tumor-specific somatic mutations and are not expressed in normal cells. the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix. The tumor and surrounding microenvironment are closely related and constantly interact. Effective immunotherapy often requires changes to the TME. V-J recombination is the unique mechanism of genetic recombination that occurs in developing lymphocytes during the early stages of T and B cell maturation. It involves somatic recombination in a nearly random fashion, which rearranges variable (V), joining (J), and, in some cases, diversity (D) gene segments. This has resulted in the highly diverse repertoire of antibodies and/or immunoglobulins (Igs) and T cell receptors (TCRs) found on B cells and T cells, respectively.

ICBcomb: a comprehensive expression database for immune checkpoint blockade combination therapy

ICBatlas: A comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles

Current transcriptome database and biomarker discovery for immunotherapy by immune checkpoint blockade

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades

Dcdb: Drug Combination Database

Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response

A Predictive Network-Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and Treatment Strategies

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors

CanImmunother: a Manually Curated Database for Identification of Cancer Immunotherapies Associating with Biomarkers, Targets, and Clinical Effects.

IMPACT: A Web Server for Exploring Immunotherapeutic Predictive and Cancer Prognostic Biomarkers

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

DrugCombDB: a Comprehensive Database of Drug Combinations Toward the Discovery of Combinatorial Therapy

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

DrugCombDB: a Comprehensive Database of Drug Combinations Toward Network Medicine and Combination Therapy

Profiling of Immune Features to Predict Immunotherapy Efficacy

TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology

A Method for Predicting Drugs That Can Boost the Efficacy of Immune Checkpoint Blockade

Large-scale public data reuse to model immunotherapy response and resistance

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts

Towards in Silico Prediction of the Immune-Checkpoint Blockade Response

Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules